Article

Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function.

Department of Anesthesiology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 08/2011; 108(33):13829-34. DOI: 10.1073/pnas.1105121108
Source: PubMed

ABSTRACT The goal of the present studies was to investigate the role of changes in hydrogen sulfide (H(2)S) homeostasis in the pathogenesis of hyperglycemic endothelial dysfunction. Exposure of bEnd3 microvascular endothelial cells to elevated extracellular glucose (in vitro "hyperglycemia") induced the mitochondrial formation of reactive oxygen species (ROS), which resulted in an increased consumption of endogenous and exogenous H(2)S. Replacement of H(2)S or overexpression of the H(2)S-producing enzyme cystathionine-γ-lyase (CSE) attenuated the hyperglycemia-induced enhancement of ROS formation, attenuated nuclear DNA injury, reduced the activation of the nuclear enzyme poly(ADP-ribose) polymerase, and improved cellular viability. In vitro hyperglycemia resulted in a switch from oxidative phosphorylation to glycolysis, an effect that was partially corrected by H(2)S supplementation. Exposure of isolated vascular rings to high glucose in vitro induced an impairment of endothelium-dependent relaxations, which was prevented by CSE overexpression or H(2)S supplementation. siRNA silencing of CSE exacerbated ROS production in hyperglycemic endothelial cells. Vascular rings from CSE(-/-) mice exhibited an accelerated impairment of endothelium-dependent relaxations in response to in vitro hyperglycemia, compared with wild-type controls. Streptozotocin-induced diabetes in rats resulted in a decrease in the circulating level of H(2)S; replacement of H(2)S protected from the development of endothelial dysfunction ex vivo. In conclusion, endogenously produced H(2)S protects against the development of hyperglycemia-induced endothelial dysfunction. We hypothesize that, in hyperglycemic endothelial cells, mitochondrial ROS production and increased H(2)S catabolism form a positive feed-forward cycle. H(2)S replacement protects against these alterations, resulting in reduced ROS formation, improved endothelial metabolic state, and maintenance of normal endothelial function.

0 Bookmarks
 · 
139 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hydrogen sulfide (H2S) is an important signaling molecule with physiological endpoints similar to those of nitric oxide (NO). Growing interest in its physiological roles and pharmacological potential has led to large sets of contradictory data. The principle cause of these discrepancies can be the common neglect of some of the basic H2S chemistry. This study investigates how the experimental outcome when working with H2S depends on its source and dose and the methodology employed. We show that commercially available NaHS should be avoided and that traces of metal ions should be removed because these can reduce intramolecular disulfides and change protein structure. Furthermore, high H2S concentrations may lead to a complete inhibition of cell respiration, mitochondrial membrane potential depolarization and superoxide generation, which should be considered when discussing the biological effects observed upon treatment with high concentrations of H2S. In addition, we provide chemical evidence that H2S can directly react with superoxide. H2S is also capable of reducing cytochrome c(3+) with the concomitant formation of superoxide. H2S does not directly react with nitrite but with NO electrodes that detect H2S. In addition, H2S interferes with the Griess reaction and should therefore be removed from the solution by Cd(2+) or Zn(2+) precipitation prior to nitrite quantification. 2-phenyl-4,4,5,5,-tetramethylimidazoline-1-oxyl 3-oxide (PTIO) is reduced by H2S, and its use should be avoided in combination with H2S. All these constraints must be taken into account when working with H2S to ensure valid data.
    Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society. 06/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Here we investigated the regulation of mitochondrial poly(ADP-ribose) polymerase 1 (PARP1) by the cAMP / protein kinase A (PKA) system during oxidative stress in U937 monocytes. Oxidative stress induced an early (10 min) mitochondrial DNA damage, and concomitant activation of PARP1 in the mitochondria. These early events were followed by a progressive mitochondrial oxidant production and nuclear PARP1 activation (by 6 hours). These processes led to a functional impairment of mitochondria, culminating in cell death of mixed (necrotic/apoptotic) type. β-adrenoceptor blockade with propranolol or inhibition of its downstream cAMP / PKA signaling attenuated, while β-adrenoceptor agonists and cAMP / PKA activators enhanced the oxidant-mediated PARP1 activation. In the presence of cAMP, recombinant PKA directly phosphorylates recombinant PARP1 on serines 465 (in the auto-modification domain) and 782 and 785 (both in the catalytic domain). Inhibition of the β-adrenergic receptor / cAMP / PKA axis protected against the oxidant-mediated cell injury. Propranolol also suppressed PARP1 activation in peripheral blood leukocytes, during LPS-induced systemic inflammation in mice. We conclude that the activation of mitochondrial PARP1 is an early, active participant in oxidant-induced cell death, which is under the control of β-adrenoceptor / cAMP / PKA axis through the regulation of PARP1 activity by PARP1 phosphorylation.
    Molecular pharmacology. 07/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hydrogen sulfide is a gasotransmitter with far-reaching effects on cell function. Studies show that, depending on the context, hydrogen sulfide can function as an ameliorative agent or as a mediator of kidney injury.
    Kidney international. 06/2014; 85(6):1255-8.

Full-text

Download
74 Downloads
Available from
May 23, 2014